Eribulin

Results: 22



#Item
1Application of Natural Resources to Drug Discovery in Eisai Research and Development of Eribulin mesylate Katsuya Tagami, Eisai Co., Ltd. Eribuin mesylate is a first-in class, non-taxane microtubule dynamics inhibitor th

Application of Natural Resources to Drug Discovery in Eisai Research and Development of Eribulin mesylate Katsuya Tagami, Eisai Co., Ltd. Eribuin mesylate is a first-in class, non-taxane microtubule dynamics inhibitor th

Add to Reading List

Source URL: apac-asia.com

Language: English - Date: 2017-05-01 03:53:28
    2EISAI UND PIQUR UNTERZEICHNEN EINEN BAHNBRECHENDEN KOOPERATIONSVERTRAG ÜBER DIE UNTERSUCHUNG VON HALAVEN® (ERIBULIN) UND PQR309 BEI SCHWER BEHANDELBAREM BRUSTKREBS Der Vertrag sieht die Anwendung von Eribulin in Kombin

    EISAI UND PIQUR UNTERZEICHNEN EINEN BAHNBRECHENDEN KOOPERATIONSVERTRAG ÜBER DIE UNTERSUCHUNG VON HALAVEN® (ERIBULIN) UND PQR309 BEI SCHWER BEHANDELBAREM BRUSTKREBS Der Vertrag sieht die Anwendung von Eribulin in Kombin

    Add to Reading List

    Source URL: www.piqur.com

    - Date: 2016-02-17 03:09:52
      3EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

      EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

      Add to Reading List

      Source URL: www.piqur.com

      Language: English - Date: 2016-02-17 03:09:52
      4Legend Open to Accrual Pending Accrual on Hold Advanced Breast Cancer

      Legend Open to Accrual Pending Accrual on Hold Advanced Breast Cancer

      Add to Reading List

      Source URL: cancer.ucsf.edu

      Language: English - Date: 2014-10-06 14:59:53
      5January 13, 2015 Eisai Co., Ltd. STATEMENT REGARDING NHS ENGLAND’S REASSESSMENT OF HALAVEN® FOR THE CANCER DRUGS FUND Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that, in

      January 13, 2015 Eisai Co., Ltd. STATEMENT REGARDING NHS ENGLAND’S REASSESSMENT OF HALAVEN® FOR THE CANCER DRUGS FUND Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that, in

      Add to Reading List

      Source URL: www.eisai.com

      Language: English - Date: 2015-01-13 01:46:50
      6State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 Williston, VTwww.dvha.vermont.gov

      State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 Williston, VTwww.dvha.vermont.gov

      Add to Reading List

      Source URL: dvha.vermont.gov

      Language: English - Date: 2015-02-20 16:02:44
      7SCHEDULE OF PHARMACEUTICAL BENEFITS EFFICIENT FUNDING OF CHEMOTHERAPY – SECTION 100 ARRANGEMENTS SUPPLEMENT This schedule is also available on the internet at www.pbs.gov.au

      SCHEDULE OF PHARMACEUTICAL BENEFITS EFFICIENT FUNDING OF CHEMOTHERAPY – SECTION 100 ARRANGEMENTS SUPPLEMENT This schedule is also available on the internet at www.pbs.gov.au

      Add to Reading List

      Source URL: www.pbs.gov.au

      Language: English - Date: 2014-10-02 00:13:48
      8Microsoft Word[removed]Eribulin Eisai PSD March 13 final.docx

      Microsoft Word[removed]Eribulin Eisai PSD March 13 final.docx

      Add to Reading List

      Source URL: www.pbs.gov.au

      Language: English - Date: 2015-03-06 00:23:42
      9HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use See full prescribing HALAVEN® safely and effectively. information for HALAVEN. HALAVEN® (eribulin mesylate) Inject

      HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use See full prescribing HALAVEN® safely and effectively. information for HALAVEN. HALAVEN® (eribulin mesylate) Inject

      Add to Reading List

      Source URL: www.accessdata.fda.gov

      Language: English - Date: 2014-08-04 14:23:47
      10U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

      U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

      Add to Reading List

      Source URL: www.fda.gov

      Language: English